EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer

Sarah Waliany, Jessica J Lin, Justin F Gainor

Trends in Cancer · 2025

DOI: 10.1016/j.trecan.2025.01.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2025. Verfasst von Sarah Waliany und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Molecular Targeted Therapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 96 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The expanding armamentarium of targeted therapies has revolutionized treatment for metastatic oncogene-addicted lung cancers. For multiple subsets, such as those harboring EGFR mutations and fusions in ALK or ROS1, successive generation of increasingly potent, selective, and brain-penetrating targeted therapies have shifted the treatment paradigm towards preferential first-line use of next-generation drugs. This evolution in clinical practice provides a lens through which to review the lessons learned from drug development in oncogene-addicted lung cancers, guided by translational insights into tumor biology and mechanisms of therapeutic resistance. For oncogenic drivers that are less sensitive to single-agent targeted therapies, rationally designed combination strategies will be needed to enable first-line use of targeted agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMolecular Targeted TherapyAntineoplastic Combined Chemotherapy ProtocolsHumansDrug Resistance, NeoplasmProtein Kinase InhibitorsMutationErbB ReceptorsNeoplasm MetastasisAnaplastic Lymphoma Kinase

Stichwörter der Autor:innen

first-line therapyoff-target resistanceon-target resistance mutationsrationally designed combination therapiestargeted therapies

Substanzen

Protein Kinase InhibitorsErbB ReceptorsAnaplastic Lymphoma Kinase

Autor:innen und Institutionen

  • Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Electronic address: jgainor@mgh.harvard.edu.

Zitieren

APA

Waliany, S., Lin, J. J., & Gainor, J. F. (2025). Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer. Trends in Cancer. https://doi.org/10.1016/j.trecan.2025.01.005

Vancouver

Waliany S, Lin JJ, Gainor JF. Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer. Trends in Cancer. 2025. doi:10.1016/j.trecan.2025.01.005

BibTeX
@article{Waliany2025,
  author = {Waliany, Sarah and Lin, Jessica J and Gainor, Justin F},
  title = {Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer},
  journal = {Trends in Cancer},
  year = {2025},
  doi = {10.1016/j.trecan.2025.01.005}
}
Kostenlos starten →